Abstract: Gel compositions containing a Michael addition elastomer formed from the reaction of a reactant molecule containing two or more Michael acceptor groups and a molecule containing one or Michael donor group with two or more active hydrogens in its molecule and capable of forming 1,4-addition products with the Michael acceptor reactants, in a topically acceptable carrier fluid. The gelled compositions may further contain a personal or healthcare active. The actives may be incorporated into the gel via either a pre or post load method.

Abstract: The present disclosure relates to gel compositions of, or containing, a non-isocyanate polyurethane (NIPU) elastomer formed from the reaction of a polycarbonate, where carbonate groups may be cyclic or non-cyclic, and a polyamine, where amines are either primary or secondary, in an optional topically acceptable carrier fluid. The gelled compositions may further contain a personal or healthcare active. The actives may be incorporated into the gel via either a pre or post load method.

Abstract: The present invention relates to gel compositions comprising a polyurethane elastomer. The polyurethane elastomer is formed from the reaction of a polyol, a polyisocyanate, and optionally a polyurethane reaction catalyst, optionally in the presence of a topically acceptable carrier fluid. In some embodiments, the gel composition comprises a personal active ingredient or a healthcare active ingredient, which may be incorporated into the gel composition via a pre-load method or a post-load method. Also provided herein are gel pastes and topical formulations comprising the polyurethane elastomers, and methods of making the same.

Abstract: The present disclosure provides a topical pharmaceutical formulation comprising uracil and a penetration enhancer, method of administration the same. Also provided is a method of treating or preventing dermatoses associated with the administration of a 5-fluorouracil or a precursor or prodrug thereof, such as capecitabine. the penetration enhancer is selected from the group consisting of dimethyl isosorbide, isopropyl myristate, isopropyl palmitate, octyldodecanol, oleic acid, oleyl alcohol, polyrides, pyrrolidone, thymol, tricaprylin, triolein, myristic acid, medium chain triglycerides, linoleic acid, lauric acid, glycofurol, glyceryl monooleate, ethyl oleate, dimethyl sulfoxide, dibutyl sebacate, and mixtures thereof.

Abstract: This invention relates generally to the use of 5?-methylthioadenosine phosphorylase (MTAP) inhibitors for the treatment of lung diseases associated with inflammation, such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Small molecule inhibitors of MTAP can sustain accumulation of endogenous MTA to therapeutically beneficial levels resulting in decreased inflammation in CF and COPD.

Abstract: This invention relates generally to the use of 5?-methylthioadenosine phosphorylase (MTAP) inhibitors for the treatment of lung diseases associated with inflammation, such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Small molecule inhibitors of MTAP can sustain accumulation of endogenous MTA to therapeutically beneficial levels resulting in decreased inflammation in CF and COPD.

Abstract: The present invention relates to treatments and therapies for anemia conditions and diseases of the blood, and more particular is a therapy for the acute and chronic treatment of sickle cell diseases and thalassemia by administration of pyridoxamine, or a pharmaceutically acceptable salt thereof, optionally in combination with an additional bioactive agent.

Abstract: The present invention relates to the synthesis, composition and use of novel moieties formed by reacting a transimination nucleophilic catalyst, molecular or polymeric, with carbonyl-containing therapeutic or cosmetic moieties. The resultant Schiff base product is highly reactive towards transimination with a biological amine. The catalyst and carbonyl-containing moiety can be molecular or polymeric, and the resultant chemical and physical properties of the Schiff base products can be engineered by appropriate selection of said catalyst. The present invention also relates to the synthesis, composition and use of novel moieties that are used as actives in sunless tanning preparations. The present invention also relates to the use of transimination nucleophilic catalysts to increase the rate at which a carbonyl-containing moiety reacts with a biological amine.

Abstract: Composite particles comprised of an optical agent(s) entrapped in a non-porous microparticle of polyorganosilsesquioxane to yield discrete microparticles, are provided. The optical agent is fully encapsulated in the interior of the silsesquioxane particle to impart optical properties that include absorption and emission in the ultraviolet and visible spectrum respectively, without otherwise interfering with the surface chemistry or surface properties of the particle. The use of these novel microparticles in a cosmetic or pharmaceutical composition provides a change in the optical appearance of the skin by either changing the apparent tone or hue, making the skin appear lighter, softer, or by photoluminescent brightening and/or by novel color sculpting under various light conditions.